6533b870fe1ef96bd12cf94a

RESEARCH PRODUCT

Posaconazole against Candida glabrata with Variable Susceptibility to Fluconazole

E SpreghiniCm MaidaS TomassettiF OrlandoD GianniniMe MiliciG ScaliseF Barchiesi

subject

Candida glabrata posaconazole azoles MICSettore MED/42 - Igiene Generale E Applicata

description

We investigated the in vitro activities of posaconazole (POS), fluconazole (FLC), amphotericin B (AMB), and caspofungin (CAS) against four clinical isolates of Candida glabrata with various susceptibilities to FLC (FLC MICs ranging from 1.0 to >64 microg/ml). POS MICs ranged from 64 microg/ml; POS MIC of 0.5 microg/ml). FLC significantly reduced the kidney burden of mice infected with the S strain (P = 0.0070) but not of those infected with the S-DD and R strains. POS was significantly effective against all three isolates at reducing the kidney fungal burden with respect to the controls (P ranging from 0.0003 to 0.029). In conclusion, our data suggest that POS may be a useful option in the management of systemic infections caused by C. glabrata. Additionally, the new triazole may be a therapeutic option in those cases where an FLC-resistant isolate is found to retain a relatively low POS MIC.

yearjournalcountryeditionlanguage
2008-06-01
10.1128/aac.00130-08http://hdl.handle.net/10447/38149